Moderna Stock News

Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.

The S&P 500 is within striking distance of entering official bull market territory. To qualify, the index would need to rise more than 20% from its previous low and hit a new all-time high.

Moderna, Inc. (MRNA) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript

Metagenomi Technologies, a startup developing treatments for genetic diseases backed by Moderna Therapeutics Inc (NASDAQ:MRNA) and Bayer AG (ETR:BAYN, OTC:BAYZF), filed for a US IPO on Friday.  Foun

Covid-19 vaccine maker Moderna said 2023 product sales hit $6.7 billion, above the company's guidance, but down more than 60% from 2022.

Moderna Inc.'s stock MRNA, +2.26% was up by 1.2% after the drug maker said it sold $6.7 billion of products in 2023. Analyst expected the company to sell $6.35 billion in products in 2023.

Moderna on Monday reported preliminary 2023 sales of $6.7 billion for its COVID vaccine, surpassing the lower end of its full-year forecast, while reiterating its goal of returning to sales growth in

Moderna's sales show the steep drop in demand for Covid products as cases and public concern about the virus dwindled front their pandemic peaks.

Moderna's mRNA-1083 vaccine, targeting COVID-19 and flu, in Phase 3, reflects innovation in combination vaccinations. Despite recent financial losses, Moderna maintains strong liquidity with $12.8 bil

The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc. NA

'Mad Money' host Jim Cramer looks back at last year's worst performers on the Nasdaq.

Moderna (MRNA) closed the most recent trading day at $108.66, moving +0.07% from the previous trading session.

Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC.

Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.